Analysis of the mechanism of action and pharmacological effects of Daliramin Hydrochloride

Daridorexant belongs to the class of orexin receptor antagonist drugs. It is one of the drug types with the latest mechanism and better tolerance for the treatment of insomnia. Unlike traditional benzodiazepine sedatives, Dalitrazen regulates the sleep-wake cycle by selectively antagonizing two orexin receptors (Orexin-1 and Orexin-2) in the brain, thereby helping patients fall asleep and maintain sleep without disturbing the natural sleep structure.

Under normal physiological conditions, orexin (also known as"wake-inducing peptides", Orexin-A and Orexin-B) is secreted by the hypothalamus and is an important neuropeptide for maintaining wakefulness. Patients with insomnia often have excessive activation of the orexin system, which prevents the brain from "turning off" at night and makes it difficult to fall asleep even if the body is tired. By blocking the binding of orexin to its receptors (OX1R and OX2R), DaliRazen reduces the transmission of arousal signals and helps the central nervous system "quiet", thereby promoting a more natural and coherent sleep process.

Pharmacologically, Dalitrazolin is a non-benzodiazepine central nervous system inhibitor that is highly selective and does not act onGABA receptors. Therefore, it will not cause excessive sedation, muscle relaxation or respiratory depression problems caused by typical sedative drugs. Its half-life is approximately 8 hours and is suitable for single oral use before bedtime. Doses of 25 mg or 50 mg are common standards. The metabolism of dalirasheng is mainly through the CYP3A4 enzyme of the liver and excreted from the body through feces and urine.

Compared with traditional sleeping pills, DaliRazen is less likely to cause residual morning drowsiness, cognitive impairment, or addiction. Most patients achieve a more physiological sleep cycle after use, improving difficulty falling asleep and nighttime awakenings, while maintaining daytime wakefulness the next day.

Therefore, as a representative of the DORA class of drugs, DaliRazen hydrochloride has a mechanism of action based on precise regulation of the central arousal pathway. It is considered a new direction in the treatment of insomnia. It is especially suitable for patients with long-term sleep disorders and will gradually replace the dominant position of traditional sleep aid drugs in clinical practice.

Reference materials:https://www.quviviq.com/